Premium
Gadolinium labeled pharmaceuticals as potential mri contrast agents for liver and biliary tract
Author(s) -
Najafi A.,
Amparo E. E.,
Johnson R. R.
Publication year - 1987
Publication title -
journal of labelled compounds and radiopharmaceuticals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 47
eISSN - 1099-1344
pISSN - 0362-4803
DOI - 10.1002/jlcr.2580240915
Subject(s) - chemistry , gadolinium , pentetic acid , liposome , magnetic resonance imaging , biliary tract , nuclear magnetic resonance , in vivo , nuclear medicine , chelation , radiology , biochemistry , medicine , physics , microbiology and biotechnology , organic chemistry , biology
Three gadolinium‐labeled compounds, potential nuclear magnetic resonance (NMR) imaging contrast agents for liver and biliary tract, were studied: 1 Gd‐DISIDA, 2( Gd‐DTPA‐Liposomes, and 3) Gd‐DTPA dihexadecylamide (Gd‐diamide). In each case, “Carrier Added” Gd‐153 with specific activity of about 5uCi/mg was used. Each labeled compound was evaluated in experimental animals. Gd‐DISIDA proved unsatisfactory because of in vivo instability. Gd‐DTPA‐Liposomes demonstrated strong toxic effects probably due to pulmonary embolism when large amounts of this compound was administered intravenously. Gd‐diamide showed good uptake in the hepatocytes with subsequent excretion into the biliary tract. Several rabbits were imaged in a 0.6T NMR imaging system before and after injection of Gd‐diamide. Pulse sequences were chosen that would yield T1‐weighted images and permit calculation of T1 relaxation times. This compound produced significant shortening of the T1 relaxation times of the liver and observable increase in intensity on the T1‐weighted images. Gd‐diamide shows promise as potential NMR contrast agent for liver and biliary tract imaging.